This site is currently implementing core features and is not ready for patient use yet.
This site is currently implementing core features and is not ready for patient use yet.
For informational purposes only — not medical advice
Get a free vaccination guide and nearby clinic recommendations — straight to your inbox.
How serious?
Risk of death
Yes
Vaccine available?
Time to symptoms
Countries affected
Active outbreaks
Vaccination (ACWY conjugate) is required for Hajj/Umrah pilgrims and strongly recommended for travel to the African meningitis belt (Sahel region) during dry season (December–June). Outbreaks can occur in close-contact settings like dormitories and military barracks.
Bacterial meningitis and septicemia caused by Neisseria meningitidis. Rapidly fatal without treatment; vaccination required for Hajj pilgrims and recommended for Africa's meningitis belt.
Symptoms | Frequency | Severity | Onset |
|---|---|---|---|
| Fever | 90% | Severe | Early |
| High fever | 70% | Severe | Early |
| Irritability | 70% | Moderate | Early |
| Neck stiffness | 75% | Severe | Early |
| Photophobia | 60% | Moderate | Early |
| Severe headache | 85% | Severe | Early |
| Vomiting | 65% | Moderate | Early |
| Chills | 55% | Moderate | Early |
| Fatigue | 50% | Mild | Early |
| Loss of appetite | 55% | Mild | Early |
| Malaise | 50% | Mild | Early |
| Myalgia | 45% | Mild | Early |
| Nausea | 55% | Mild | Early |
| Arthralgia | 25% | Mild | Early |
| Back pain | 20% | Mild | Early |
| Sore throat | 25% | Mild | Early |
| Swollen lymph nodes | 20% | Mild | Early |
| Confusion | 40% | Severe | Peak |
| Petechiae | 65% | Critical | Peak |
| Rash | 70% | Severe | Peak |
| Altered consciousness | 30% | Critical | Peak |
| Bruising | 25% | Severe | Peak |
| Dehydration | 35% | Moderate | Peak |
| Hemorrhage | 15% | Critical | Peak |
| Hypotension | 30% | Critical | Peak |
| Seizures | 20% | Critical | Peak |
| Shock | 12% | Critical | Peak |
| Tachycardia | 60% | Moderate | Peak |
Severe bacterial infection of the membranes surrounding the brain and spinal cord.
Meningococcal disease is a severe bacterial infection caused by Neisseria meningitidis, a gram-negative diplococcus with 13 serogroups, of which 6 cause nearly all disease: A, B, C, W, X, and Y. Transmission occurs via respiratory droplets and close contact (kissing, shared utensils, crowded living). Asymptomatic nasopharyngeal carriage rate is 5–10% (up to 25% in adolescents). The bacterium can invade the bloodstream causing meningococcemia and/or cross the blood-brain barrier causing meningitis. The disease can progress from first symptoms to death within 24 hours, making it one of the most feared bacterial infections. Case fatality: 10–15% even with optimal treatment; up to 50% in meningococcemia with purpura fulminans.
MEDICAL EMERGENCY — seek care IMMEDIATELY (minutes count):
Non-blanching petechial or purpuric rash (do the glass test: press a glass tumbler against rash — if spots do NOT fade, call emergency services)
Severe headache with neck stiffness and high fever
Photophobia (light hurting the eyes) with fever
Altered consciousness: confusion, drowsiness, difficult to wake
Seizures
Cold hands and feet with fever (circulatory compromise)
Rapid breathing or difficulty breathing
In babies: bulging fontanelle, high-pitched or moaning cry, pale/blotchy skin, refusing to feed, stiff body or floppy/unresponsive
Most common signs and symptoms
Incubation: 2–10 days (typically 3–4 days). Clinical presentations:
Meningococcal meningitis (most common form, ~50% of cases):
Sudden onset severe headache
High fever, neck stiffness (nuchal rigidity), photophobia — classic meningeal triad
Nausea and vomiting (often projectile)
Altered mental status: confusion → drowsiness → coma
Kernig sign (inability to extend knee when hip flexed) and Brudzinski sign (neck flexion causes hip/knee flexion)
Seizures (20–30%, especially in children)
In infants: irritability, bulging fontanelle, poor feeding, high-pitched cry (classic signs may be absent)
Meningococcemia (septicemia — ~40% of cases, may occur with or without meningitis):
Rapid onset fever with rigors
Petechial/purpuric rash: Initially non-blanching petechiae → coalescing purpura → purpura fulminans (disseminated intravascular coagulation with hemorrhagic necrosis)
Glass test: Press a clear glass against the rash — if it does NOT fade, suspect meningococcal septicemia → EMERGENCY
Tachycardia, hypotension, cold extremities (circulatory collapse)
Multi-organ failure in fulminant cases
Limb ischemia (may require amputation in survivors)
Fulminant course: Can progress from first symptom to death in <12–24 hours.
Knowing the symptoms is the first step to a quick response.
Typical disease course:
Critical feature: Fulminant meningococcal septicemia can progress from apparent good health to death within 12–24 hours. The non-blanching petechial rash is a red-flag sign requiring immediate emergency care.
How this disease is identified
Meningococcal disease is a medical emergency — do NOT delay treatment for diagnostics.
Blood cultures: Obtain BEFORE antibiotics if possible (positive in 40–70%)
Lumbar puncture (when safe): CSF shows: elevated WBC (polymorphonuclear predominance), elevated protein, decreased glucose, gram-negative diplococci on Gram stain (60–90% sensitivity) – Contraindicated if: signs of raised ICP, coagulopathy, cardiorespiratory compromise, local skin infection
CSF/blood PCR: Most sensitive (>90%); can detect N. meningitidis even after antibiotic administration
Latex agglutination: Rapid serogroup identification from CSF
Complete blood count: Leukocytosis or leukopenia (poor prognosis if leukopenic); thrombocytopenia; elevated CRP/procalcitonin
Coagulation panel: DIC screen (prolonged PT/aPTT, elevated D-dimer, low fibrinogen) — critical in meningococcemia
Skin biopsy of petechiae: Can confirm diagnosis even after antibiotics
Critical rule: If meningococcal disease suspected → give parenteral antibiotics IMMEDIATELY, then investigate.
Available treatment methods
IMMEDIATE TREATMENT IS LIFE-SAVING. Minutes matter.
Pre-hospital (GP/clinic):
Hospital treatment:
First-line: Ceftriaxone 2 g IV every 12 hours (or cefotaxime 2 g IV every 4–6 hours) × 7 days
Penicillin-susceptible confirmed: Benzylpenicillin IV may be used
Adjunctive dexamethasone: 0.15 mg/kg IV every 6 hours × 4 days — give before or with first antibiotic dose; reduces mortality and neurological sequelae in bacterial meningitis (de Gans 2002 NEJM)
Meningococcal septicemia (aggressive resuscitation):
Aggressive IV fluid resuscitation (may need 40–60 mL/kg in first hour)
Vasopressor support (noradrenaline first-line)
Fresh frozen plasma, platelets if DIC present
ICU admission; may require ventilation, renal replacement therapy
Activated protein C was used historically but no longer recommended
Chemoprophylaxis for close contacts:
Ciprofloxacin 500 mg PO single dose (adults) or rifampicin 600 mg BID × 2 days
Give to household contacts, kissing contacts, healthcare workers with unprotected direct exposure to secretions
Administer within 24 hours of case identification
Most cases are effectively treated with early diagnosis.
How to protect yourself
Vaccination:
Meningococcal ACWY conjugate vaccine (MenACWY — Menveo, Nimenrix, MenQuadfi): Conjugate vaccines provide T-cell dependent immunity (longer lasting than polysaccharide). Single dose; booster every 5 years if ongoing risk. Licensed from age 2 months (varies by product).
Meningococcal B vaccine (MenB — Bexsero, Trumenba): Covers serogroup B (common in Europe, Americas). 2-dose schedule. Not combined with ACWY.
Meningococcal polysaccharide (MPSV4): Older vaccine; less immunogenic; no longer preferred
Pentavalent ACYWX: In development; critical for Africa where serogroup X is emerging
MenAfriVac (conjugate A): Single dose; eliminated serogroup A epidemics in Africa's meningitis belt since 2010 (one of the greatest vaccine successes)
Travel-specific requirements:
Hajj/Umrah (Saudi Arabia): Meningococcal ACWY vaccination REQUIRED for visa; must be given ≥10 days before arrival
Meningitis belt travel (Sahel): MenACWY recommended, especially during dry season (December–June)
College students living in dormitories: MenACWY + consider MenB
Outbreak response: WHO threshold: 10 cases/100,000/week for 2 consecutive weeks → mass vaccination campaign.
Preparation is the best protection.
Risk to travelers:
High risk: Sub-Saharan Africa meningitis belt during dry season (December–June); Hajj/Umrah pilgrimage; crowded mass gatherings
Moderate risk: Backpackers and youth travelers in shared accommodation (hostels, dormitories)
MenACWY vaccine required: Hajj/Umrah visa (Saudi Arabia mandates it)
MenACWY vaccine recommended: Travel to meningitis belt, prolonged close contact with local populations, healthcare workers in outbreak settings
Carry a meningococcal vaccination certificate when traveling to Saudi Arabia or affected countries
Seek immediate medical care for fever + non-blanching rash — this is a life-threatening emergency
Serogroup B vaccine additionally recommended for prolonged stays in settings with known serogroup B activity (some European countries)
Vaccination does not cover all serogroups — maintain awareness of symptoms regardless
Statistics and geographic data
Global burden: WHO estimates 1.2 million cases and 135,000 deaths annually (2019 pre-COVID). Epidemiology varies by serogroup and region:
Africa meningitis belt (26 countries from Senegal to Ethiopia): Historically devastating serogroup A epidemics during dry season (December–June)
MenAfriVac introduction (2010) eliminated serogroup A epidemics — now serogroups C, W, and X are emerging
Europe/Americas: Serogroups B, C, W, Y predominant
outbreaks in universities, military
serogroup W increasing
Asia: Variable
serogroup A (India, China), B, C, W
underreported
Middle East: Hajj-associated outbreaks historically drove global spread (2000 Hajj W135 epidemic)
Age distribution: Bimodal — infants (<1 year: highest incidence) and adolescents/young adults (15–25: high carriage rate)
Risk factors: Crowded living (dorms, barracks, Hajj), complement deficiency, asplenia, HIV, active/passive smoking, preceding viral URI
Who is most at risk
Travel to the African meningitis belt (sub-Saharan Africa), Hajj pilgrimage, living in close quarters (dormitories, military barracks), complement deficiency or asplenia, adolescents and young adults (15–24 years), infants under 1 year, exposure during outbreaks.
Potential complications
Meningococcal disease carries severe morbidity even with optimal treatment:
Mortality: 10–15% with treatment
up to 50% in fulminant meningococcemia
death can occur within hours
Limb amputation: Purpura fulminans causes ischemic necrosis of extremities
10–20% of survivors require amputation of fingers, toes, or limbs
Hearing loss: 5–10% of meningitis survivors
may be bilateral and profound
cochlear implant may be needed
Neurological sequelae (10–20%): Cognitive impairment, seizure disorder, motor deficits, hydrocephalus, cranial nerve palsies
Skin scarring: Extensive necrotic skin lesions requiring grafting
Adrenal hemorrhage (Waterhouse-Friderichsen syndrome): Bilateral adrenal infarction → acute adrenal insufficiency
high mortality
Renal failure: From shock, DIC, and myoglobin deposition
Psychological impact: PTSD, anxiety, depression in survivors and families
Arthritis: Reactive arthritis in 5–10% during convalescence (immune-mediated)
Long-term disability: Up to 40% of survivors have at least one residual disability
Expected outcomes and recovery
With treatment: CFR 8–15% (meningitis), 20–40% (meningococcemia/septicemia).
Without treatment: Nearly 100% fatal.
Sequelae in survivors:
Hearing loss: 5–10%.
Neurological deficits: 10–20% (cognitive impairment, seizures, motor deficits).
Limb amputation (due to purpura fulminans/DIC): 5–10% of meningococcemia survivors.
Renal injury, adrenal hemorrhage (Waterhouse-Friderichsen syndrome).
Prognostic factors: Age <1 year or >60 years, rapid progression, meningococcemia without meningitis, DIC, and coma predict poor outcomes.
Recovery: Survivors without major sequelae typically recover fully within 2–4 weeks.
This disease is vaccine-preventable. Effective protection is available through vaccination.
Talk to a travel health specialist about the recommended schedule before your trip.
Find a vaccination clinic →The content on this page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. If you have health concerns, consult a qualified healthcare professional. Medova is not a medical service provider.
Full terms of useGeographic distribution and active outbreaks
Recent epidemiological data from the World Health Organization Global Health Observatory.
Source: WHO GHO OData ↗
Source: WHO GHO OData ↗
This data is provided for informational purposes. Please consult official WHO sources for the most current information.
View WHO data source →| Flag | Country | Risk level |
|---|---|---|
 | Cameroon | High risk |
 | Ghana | High risk |
 | Nigeria | High risk |
 | South Sudan | High risk |
 | Benin | High risk |
 | Burkina Faso | High risk |
 | Mali | High risk |
 | Sudan | High risk |
 | Niger | High risk |
 | Central African Republic | High risk |
Know which vaccine you need? Great. Not sure? Just tell us your destination — we will figure it out and match you with a clinic. Free, no obligation.
A complete health preparation guide for Hajj and Umrah pilgrims. Covers mandatory meningococcal vaccination, recommended vaccines, extreme heat safety, crowd-related risks, and what to pack for a safe pilgrimage.